Primary Osteoarthritis Market Research Report: By Type (Knee, Hand, Neck, Hip, Wrist, Spinal, and Shoulder Osteoarthritis), Product Type, Drug Class (Combination Drug, LTA, ICS, SABA, LABA), Route of Administration, End User – Global Forecast till 2027
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Route of Administration Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Primary osteoarthritis Market, by Type
6.1 Introduction
6.2 Knee Osteoarthritis
6.2.1 Market Estimates & Forecast, 2020 – 2027
6.3 Hip Osteoarthritis
6.3.1 Market Estimates & Forecast, 2020 – 2027
6.4 Wrist Osteoarthritis
6.4.1 Market Estimates & Forecast, 2020 – 2027
6.5 Spinal Osteoarthritis
6.5.1 Market Estimates & Forecast, 2020 – 2027
6.5 Others
Chapter 7. Global Primary osteoarthritis Market, by diagnosis
7.1 Introduction
7.2 Imaging
7.2.1 Market Estimates & Forecast, 2020 – 2027
7.2.2 X-rays
7.2.2.1 Market Estimates & Forecast, 2020 – 2027
7.2.3 Magnetic resonance imaging (MRI)
7.2.3.1 Market Estimates & Forecast, 2020 – 2027
7.2.4 Others
7.3 Joint fluid analysis
7.3.1 Market Estimates & Forecast, 2020 – 2027
7.4 Others
Chapter 8. Global Primary osteoarthritis Market, by Treatment
8.1 Introduction
8.2 Medication
8.2.1 Market Estimates & Forecast, 2020 – 2027
8.2.2 Analgesics
8.2.2.1 Market Estimates & Forecast, 2020 – 2027
8.2.4.1 Acetaminophen
8.2.4.1.1 Market Estimates & Forecast, 2020 – 2027
8.2.4.2 Duloxetine
8.2.4.2.1 Market Estimates & Forecast, 2020 – 2027
8.2.4.3 Others
8.2.4.3.1 Market Estimates & Forecast, 2020 – 2027
8.2.3 Non-steroidal anti-inflammatory drugs
8.2.3.1 Market Estimates & Forecast, 2020 – 2027
8.2.3.2 Aspirin
8.2.3.2.1 Market Estimates & Forecast, 2020 – 2027
8.2.3.3 Ibuprofen
8.2.3.3.1 Market Estimates & Forecast, 2020 – 2027
8.2.3.4 Naproxen sodium/ naproxen
8.2.3.4.1 Market Estimates & Forecast, 2020 – 2027
8.2.3.5 Others
8.2.4 Others
8.3 Therapies
8.3.1 Market Estimates & Forecast, 2020 – 2027
8.4 Surgery
8.4.1 Market Estimates & Forecast, 2020 – 2027
8.5 Others
Chapter 9. Global Primary osteoarthritis Market, by Route of Administration
9.1 Introduction
9.2 Oral
9.2.1 Market Estimates & Forecast, 2020 – 2027
9.3 Inhaler
9.3.1 Market Estimates & Forecast, 2020 – 2027
9.4 Intravenous
9.4.1 Market Estimates & Forecast, 2020 – 2027
9.5 Subcutaneous
9.5.1 Market Estimates & Forecast, 2020 – 2027
9.6 Others
Chapter 10. Global Primary osteoarthritis Market, by End User
10.1 Introduction
10.2 Hospitals & Diagnostic Centers
10.2.1 Market Estimates & Forecast, 2020 – 2027
10.3 Academic Institutes
10.3.1 Market Estimates & Forecast, 2020 – 2027
10.4 Pharmaceutical & Biotechnology
10.4.1 Market Estimates & Forecast, 2020 – 2027
10.5 Others
10.5.1 Market Estimates & Forecast, 2020 – 2027
Chapter. 11 Global Primary osteoarthritis Market, by Region
11.1 Introduction
11.2 Americas
11.2.1 North America
11.2.1.1 U.S.
11.2.1.2 Canada
11.2.2 South America
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 Italy
11.3.1.4 Spain
11.3.1.5 U.K
11.3.1.6 Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 Republic of Korea
11.4.6 Rest of Asia Pacific
11.5 The Middle East & Africa
11.5.1 United Arab Emirates
11.5.2 Saudi Arabia
11.5.3 Rest of the Middle East & Africa
Chapter 12 Company Landscape
12.1 Introduction
12.2 Market Share Analysis
12.3 Key Development & Strategies
12.3.1 Key Developments
Chapter 13 Company Profiles
13.1 Johnson & Johnson Limited
13.1.1 Company Overview
13.1.2 Drug Class Overview
13.1.3 Financials
13.1.4 SWOT Analysis
13.2 Novartis AG
13.2.1 Company Overview
13.2.2 Drug Class Overview
13.2.3 Financial Overview
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.3 Merck & Co. Inc.
13.3.1 Company Overview
13.3.2 Drug Class Overview
13.3.3 Financial Overview
13.3.4 Key Development
13.3.5 SWOT Analysis
13.4 Abbott Laboratories
13.4.1 Company Overview
13.4.2 Drug Class/Business Segment Overview
13.4.3 Financial Overview
13.4.4 Key Development
13.4.5 SWOT Analysis
13.5 Eli Lilly and Company
13.5.1 Company Overview
13.5.2 Drug Class Overview
13.5.3 Financial overview
13.5.4 Key Developments
13.6 Abiogen Pharma
13.6.1 Company Overview
13.6.2 Drug Class Overview
13.6.3 Financial Overview
13.6.4 Key Developments
13.7 Ampio pharmaceuticals
13.7.1 Overview
13.7.2 Drug Class Overview
13.7.3 Financials
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.8 BioDelivery Sciences International
13.8.1 Company Overview
13.8.2 Drug Class/Business Segment Overview
13.8.3 Financial Overview
13.8.4 Key Development
13.8.5 SWOT Analysis
13.9 Pfizer Inc.
13.9.1 Company Overview
13.9.2 Drug Class Overview
13.9.3 Financial overview
13.9.4 Key Developments
13.10 Others
Chapter 14 MRFR Conclusion
14.1 Key Findings
14.1.1 From CEO’s View Point
14.1.2 Unmet Needs of the Market
14.2 Key Companies to Watch
14.3 Prediction of Pharmaceutical industry
Chapter 15 Appendix
LIST OF TABLES
Table 1 Primary osteoarthritis Industry Synopsis, 2020 – 2027
Table 2 Primary osteoarthritis Market Estimates and Forecast, 2020 – 2027, (USD Million)
Table 3 Primary osteoarthritis Market by Region, 2020 – 2027, (USD Million)
Table 4 Primary osteoarthritis Market by Disease Type, 2020 – 2027, (USD Million)
Table 5 Primary osteoarthritis Market by Product Type, 2020 – 2027, (USD Million)
Table 6 Primary osteoarthritis Market by Drug Class, 2020 – 2027, (USD Million)
Table 7 Primary osteoarthritis Market by Route of Administration, 2020 – 2027, (USD Million)
Table 8 Primary osteoarthritis Market by End Users, 2020 – 2027, (USD Million)
Table 9 North America Primary osteoarthritis Market by Disease Type, 2020 – 2027, (USD Million)
Table 10 North America Primary osteoarthritis Market by Product Type, 2020 – 2027, (USD Million)
Table 11 North America Primary osteoarthritis Market by Drug Class, 2020 – 2027, (USD Million)
Table 12 North America Primary osteoarthritis Market by Route of Administration, 2020 – 2027, (USD Million)
Table 13 North America Primary osteoarthritis Market by End User, 2020 – 2027, (USD Million)
Table 14 US Primary osteoarthritis Market by Disease Type, 2020 – 2027, (USD Million)
Table 15 US Primary osteoarthritis Market by Product Type, 2020 – 2027, (USD Million)
Table 16 US Primary osteoarthritis Market by Drug Class, 2020 – 2027, (USD Million)
Table 17 US Primary osteoarthritis Market by Route of Administration, 2020 – 2027, (USD Million)
Table 18 US Primary osteoarthritis Market by End User, 2020 – 2027, (USD Million)
Table 19 Canada Primary osteoarthritis Market by Disease Type, 2020 – 2027, (USD Million)
Table 20 Canada Primary osteoarthritis Market by Product Type, 2020 – 2027, (USD Million)
Table 21 Canada Primary osteoarthritis Market by Drug Class, 2020 – 2027, (USD Million)
Table 22 Canada Primary osteoarthritis Market by Route of Administration, 2020 – 2027, (USD Million)
Table 23 Canada Primary osteoarthritis Market by End User, 2020 – 2027, (USD Million)
Table 24 South America Primary osteoarthritis Market by Disease Type, 2020 – 2027, (USD Million)
Table 25 South America Primary osteoarthritis Market by Product Type, 2020 – 2027, (USD Million)
Table 26 South America Primary osteoarthritis Market by Drug Class, 2020 – 2027, (USD Million)
Table 27 South America Primary osteoarthritis Market by Route of Administration, 2020 – 2027, (USD Million)
Table 28 South America Primary osteoarthritis Market by End User, 2020 – 2027, (USD Million)
Table 29 Europe Primary osteoarthritis Market by Disease Type, 2020 – 2027, (USD Million)
Table 30 Europe Primary osteoarthritis Market by Product Type, 2020 – 2027, (USD Million)
Table 31 Europe Primary osteoarthritis Market by Drug Class, 2020 – 2027, (USD Million)
Table 32 Europe Primary osteoarthritis Market by Route of Administration, 2020 – 2027, (USD Million)
Table 33 Europe Primary osteoarthritis Market by End User, 2020 – 2027, (USD Million)
Table 34 Western Europe Primary osteoarthritis Market by Disease Type, 2020 – 2027, (USD Million)
Table 35 Western Europe Primary osteoarthritis Market by Product Type, 2020 – 2027, (USD Million)
Table 36 Western Europe Primary osteoarthritis Market by Drug Class, 2020 – 2027, (USD Million)
Table 37 Western Europe Primary osteoarthritis Market by Route of Administration, 2020 – 2027, (USD Million)
Table 38 Western Europe Primary osteoarthritis Market by End User, 2020 – 2027, (USD Million)
Table 39 Eastern Europe Primary osteoarthritis Market by Disease Type, 2020 – 2027, (USD Million)
Table 40 Eastern Europe Primary osteoarthritis Market by Product Type, 2020 – 2027, (USD Million)
Table 41 Eastern Europe Primary osteoarthritis Market by Drug Class, 2020 – 2027, (USD Million)
Table 42 Eastern Europe Primary osteoarthritis Market by Route of Administration, 2020 – 2027, (USD Million)
Table 43 Eastern Europe Primary osteoarthritis Market by End User, 2020 – 2027, (USD Million)
Table 44 Asia Pacific Primary osteoarthritis Market by Disease Type, 2020 – 2027, (USD Million)
Table 45 Asia Pacific Primary osteoarthritis Market by Product Type, 2020 – 2027, (USD Million)
Table 46 Asia Pacific Primary osteoarthritis Market by Drug Class, 2020 – 2027, (USD Million)
Table 47 Asia Pacific Primary osteoarthritis Market by Route of Administration, 2020 – 2027, (USD Million)
Table 48 Asia Pacific Primary osteoarthritis Market by End User, 2020 – 2027, (USD Million)
Table 49 The Middle East & Africa Primary osteoarthritis Market by Disease Type, 2020 – 2027, (USD Million)
Table 50 The Middle East & Africa Primary osteoarthritis Market by Product Type, 2020 – 2027, (USD Million)
Table 51 The Middle East & Africa Primary osteoarthritis Market by Drug Class, 2020 – 2027, (USD Million)
Table 52 The Middle East & Africa Primary osteoarthritis Market by Route of Administration, 2020 – 2027, (USD Million)
Table 53 The Middle East & Africa Primary osteoarthritis Market by End User, 2020 – 2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Primary osteoarthritis Market
Figure 3 Segmentation Market Dynamics for Primary osteoarthritis Market
Figure 4 Global Primary osteoarthritis Market Share, by Disease Type 2020
Figure 5 Global Primary osteoarthritis Market Share, by Product Type 2020
Figure 6 Global Primary osteoarthritis Market Share, by Drug Class, 2020
Figure 8 Global Primary osteoarthritis Market Share, by Route of Administration, 2020
Figure 9 Global Primary osteoarthritis Market Share, by End Users, 2020
Figure 10 Global Primary osteoarthritis Market Share, by Region, 2020
Figure 11 North America Primary osteoarthritis Market Share, by Country, 2020
Figure 12 Europe Primary osteoarthritis Market Share, by Country, 2020
Figure 13 Asia Pacific Primary osteoarthritis Market Share, by Country, 2020
Figure 14 The Middle East & Africa Primary osteoarthritis Market Share, by Country, 2020
Figure 15 Global Primary osteoarthritis Market: Company Share Analysis, 2020 (%)
Figure 16 Johnson & Johnson Limited : Key Financials
Figure 17 Johnson & Johnson Limited : Segmental Revenue
Figure 18 Johnson & Johnson Limited : Geographical Revenue
Figure 19 Novartis AG: Key Financials
Figure 20 Novartis AG: Segmental Revenue
Figure 21 Novartis AG: Geographical Revenue
Figure 22 Merck & Co. Inc.: Key Financials
Figure 23 Merck & Co. Inc.: Segmental Revenue
Figure 24 Merck & Co. Inc.: Geographical Revenue
Figure 25 Abbott Laboratories: Key Financials
Figure 26 Abbott Laboratories: Segmental Revenue
Figure 27 Abbott Laboratories: Geographical Revenue
Figure 28 Eli Lilly and Company: Key Financials
Figure 29 Eli Lilly and Company: Segmental Revenue
Figure 30 Eli Lilly and Company: Geographical Revenue
Figure 32 Abiogen Pharma : Key Financials
Figure 33 Abiogen Pharma : Segmental Revenue
Figure 34 Abiogen Pharma : Geographical Revenue
Figure 35 Ampio pharmaceuticals: Key Financials
Figure 36 Ampio pharmaceuticals: Segmental Revenue
Figure 37 Ampio pharmaceuticals: Geographical Revenue
Figure 38 BioDelivery Sciences International: Key Financials
Figure 39 BioDelivery Sciences International: Segmental Revenue
Figure 40 BioDelivery Sciences International: Geographical Revenue
Figure 41 Pfizer Inc.: Key Financials
Figure 42 Pfizer Inc.: Segmental Revenue
Figure 43 Pfizer Inc.: Geographical Revenue
Speak to Analyst
Request a Free Sample
Primary Osteoarthritis Market Scenario
Arthritis refers to inflammation of the joint, accompanied by joint pain and stiffness. It may be acute or chronic. Obesity, infections, crystal deposition, joint injury, and old age are some of the common causes associated with arthritis. Osteoarthritis and rheumatoid arthritis are two common types of arthritis. Osteoarthritis is a chronic disease, which affects joints, including ligament, cartilage, joint lining, and underlying bones. This disease results in joint pain and stiffness due to the breakdown of cartilage. It is also known as Degenerative Joint Disease (DJD). Primary osteoarthritis and secondary osteoarthritis are the two major forms of osteoarthritis. Primary osteoarthritis results from abnormal stress on weight-bearing joints. This is prevalent mostly in the aging population.
Physical therapy, occupational therapy, chronic pain class, and braces are some of the therapies associated with osteoarthritis. Moreover, osteoarthritis treatment includes surgical procedures such as lubrication injections, cortisone shots, and joint replacement. Rising incidences of surgeries, increasing technological advancements, increasing number of pipeline drugs, and rising awareness about health care are some of the key factors driving the growth of the osteoarthritis market. In addition, rising disposable income in developing countries is also fueling the growth of the osteoarthritis market.
However, stringent regulatory policies and less adoption of osteoarthritis treatment are restraining the growth of the osteoarthritis market. In addition, side effects associated with osteoarthritis medications are also impeding the growth of Primary Osteoarthritis Market.
The market for primary osteoarthritis is expected to grow at a CAGR of approximately 8.3% during the forecast period 2017-2023.
Intended Audience
- Primary Osteoarthritis Drug Suppliers
- Primary Osteoarthritis Drug Manufacturers
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities
Segmentation
The primary osteoarthritis market is segmented on the basis of type, diagnosis, treatment, and end-users.
On the basis of the type, the market is segmented into knee osteoarthritis, hand osteoarthritis, neck osteoarthritis, hip osteoarthritis, wrist osteoarthritis, spinal osteoarthritis, shoulder osteoarthritis, and others
On the basis of the diagnosis, the Primary Osteoarthritis Market is segmented into imaging, joint fluid analysis, and others. The imaging segment is further classified into divided X-rays, Magnetic resonance imaging (MRI), and others.
On the basis of the treatment, the Primary Osteoarthritis Market is segmented into medication, therapies, surgery, and others. The medication segment can be classified into analgesics and non-steroidal anti-inflammatory drugs. The analgesics segment is further classified as acetaminophen, duloxetine, and others. The non-steroidal anti-inflammatory drugs can be further classified into aspirin, ibuprofen, naproxen sodium/ naproxen, and others.
On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.
Research Methodology 
Sources: Annual reports, Press release, White paper, and Company presentation
Key Players
The emergence of new and cost-effective medication options for the treatment of osteoarthritis could open up new opportunities for new players in the osteoarthritis market. In addition, emerging markets, such as India and China, could also open new opportunities for new players. Increasing number of strategic alliances between various companies, rising number of product innovations, and increase in the number of clinical trials for pain reliving biologic drugs, such as anti-NGFs, are among the recent market trends in the Primary Osteoarthritis Market.
Some of key the players in the primary osteoarthritis market are Abbott Laboratories (U.S.), Johnson & Johnson Limited (U.S.), Novartis AG (Switerzland), Pfizer, Inc. (U.S.), and Eli Lilly and Company (U.S.), Abiogen Pharma (Italy), Ampio pharmaceuticals (U.S.), BioDelivery Sciences International (U.S.), CrystalGenomics (South Korea), Daiichi Sankyo (Japan), Eli Lilly (U.S.), Horizon Pharma (Republic of Ireland), Iroko Pharmaceuticals (U.S.), Merck & Co. Ltd (U.S.), Nuvo Research (U.S.), Regeneus (Australia), Sanofi (France), SantoSolve (U.S.), Smith & Nephew (UK), Winston Pharmaceuticals (India).
Regional Analysis
The primary osteoarthritis market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.
Currently, North America dominates the osteoarthritis market, followed by Europe. This is due to the rising prevalence of osteoarthritis diseases and growing geriatric population in these regions. In addition, increasing access to health care insurance, especially in the U.S., is also influencing the growth of the Primary Osteoarthritis Market.
The European primary osteoarthritis market is expected to witness rapid growth owing to the high investment in various private and government-funded research and development programs in the region and increased spending on pharmaceutical and biotechnology industry development.
Asia is expected to be the fastest growing market in the next five years. This is due to the rising healthcare infrastructure and increasing government initiatives for better health care facilities in this region. Moreover, a large patient population base is driving the growth of the Primary Osteoarthritis Market in this region.
The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of healthcare infrastructure and growing emphasis on research and development in the healthcare sector.
Frequently Asked Questions (FAQ) :
The primary osteoarthritis market CAGR would be 8.3% during the forecast period.
North America would dominate the primary osteoarthritis market.
Asia Pacific region would be the fastest-growing primary osteoarthritis market.
The primary osteoarthritis market report includes end users like research organization, medical institutes, hospitals & clinics, and others.
Stringent regulatory procedures could hold back the primary osteoarthritis market growth.
